Immune modulating nanoparticles for the treatment of ocular diseases.

Abstract

Ocular diseases are increasingly influencing people's quality of life. Complicated inflammatory mechanisms involved in the pathogenic process of ocular diseases make inflammation-targeting treatment a potential therapeutic approach. The limited efficacy of conventional anti-inflammatory therapeutic strategies, caused by various objective factors, such as complex ocular biological barriers, and subjective factors, such as poor compliance, are promoting the development of new therapeutic methods. With the advantages of considerable tissue permeability, a controllable drug release rate, and selective tissue targeting ability, nanoparticles have successfully captured researchers' attention and have become a research hotspot in treating ocular diseases. This review will focus on the advantages of nanosystems over traditional therapy, the anti-inflammation mechanisms of nanoparticles, and the anti-inflammatory applications of nanoparticles in different ocular diseases (ocular surface diseases, vitreoretinopathy, uveal diseases, glaucoma, and visual pathway diseases). Furthermore, by analyzing the current situation of nanotherapy and the challenges encountered, we hope to inspire new ideas and incentives for designing nanoparticles more consistent with human physiological characteristics to make progress based on conventional treatments. Overall, some progress has been made in nanoparticles for the treatment of ocular diseases, and nanoparticles have rather broad future clinical translation prospects. Graphical abstract.

• Authors: Lianfei Fang, Jin Liu, Zeyang Liu, Huifang Zhou
• Journal: Journal of nanobiotechnology (J Nanobiotechnology) Vol. 20 Issue 1 Pg. 496 (Nov 24 2022) ISSN: 1477-3155 [Electronic] England
• PMID: 36424630 (Publication Type: Journal Article, Review)
• Copyright: © 2022. The Author(s).

Topics

• Humans
• Quality of Life
• Eye
• Nanoparticles (therapeutic use)
• Administration, Ophthalmic
• Eye Diseases (drug therapy)